The ins and outs of selective kinase inhibitor development.
Nuffield Department of Clinical Medicine, Structural Genomics Consortium, University of Oxford, Oxford, UK.
Susanne
S
Müller
Nuffield Department of Clinical Medicine, Structural Genomics Consortium, University of Oxford, Oxford, UK.
Apirat
A
Chaikuad
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Nathanael S
http://orcid.org/0000-0001-5354-7403
NS
Gray
Nuffield Department of Clinical Medicine, Structural Genomics Consortium, University of Oxford, Oxford, UK and the Institute for Pharmaceutical Chemistry and Buchmann Institute for Molecular Life Sciences, Johann Wolfgang Goethe-University, Frankurt am Main, Germany.
Stefan
S
Knapp
D000495:Allosteric Site; D020134:Catalytic Domain; D018360:Crystallography, X-Ray; D017277:Drug Approval; D015195:Drug Design; D055808:Drug Discovery; D006801:Humans; D011487:Protein Conformation; D047428:Protein Kinase Inhibitors / Q000138:chemical synthesis / Q000737:chemistry*; D011494:Protein Kinases / Q000737:chemistry*; D021281:Quantitative Structure-Activity Relationship; D054852:Small Molecule Libraries / Q000138:chemical synthesis / Q000737:chemistry*; D014481:United States; D014486:United States Food and Drug Administration
D047428:Protein Kinase Inhibitors; D054852:Small Molecule Libraries; D011494:Protein Kinases